SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ChiRex (CHRX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: m meixlER who wrote (19)3/12/1997 9:53:00 AM
From: Haseltine   of 130
 
SEPR needs more cash as Silverman indicated. I don't see anything wrong with CHRX. They have beat every quarterly earnings estimate so far. I also think CHRX is a strong buy based on projected earnings growth and the accelerating trend towards outsourcing in the pharmaceutical industry. It will be interesting to see what happens to the stock price once Sepracor is out of the stock. Analysts are projecting 98 EPS in the $1 range--this should make it a $20 stock within the next 12 months.

Note: Sepracor does not have a seat on the ChiRex Board of Directors according to SEC documents.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News